Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257420 | 0.85 | CRBN (0.48) | CRBNDDB1HTTLMNAMAPK1 | |
| SCHEMBL22144104 | 0.80 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL21402687 | 0.79 | CRBN (0.50) | CRBNDDB1HTT | |
| SCHEMBL29257434 | 0.78 | CRBN (0.56) | CRBNDDB1PARK7 | |
| SCHEMBL24421112 | 0.77 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL29614573 | 0.77 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL24421043 | 0.77 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL25833431 | 0.77 | CRBN (0.46) | CRBNDDB1HTTLMNAMAPK1 | |
| SCHEMBL5476342 | 0.75 | ELANE (0.45) | CRBNDDB1L3MBTL1 | |
| SCHEMBL24421380 | 0.74 | DDB1 (0.44) | CRBNDDB1GSPT1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS, INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | CRBN 82/4885DDB1 144/4885GSPT1 2008/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | CRBN 82/4885DDB1 144/4885GSPT1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.